BioSpace News Archive

SUBLOCADE Expected to be Available to U.S. Patients in Q1 2018 This announcement contains inside information. [30-November-2017] RICHMOND, Va. and SLOUGH, England, Nov. 30, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved SUBLOCADE TM (buprenorphine extended- release) inj

The results showed that CK-2127107 increased the force generated by the tibialis anterior muscle versus placebo in response to nerve stimulation in a dose, plasma concentration, and frequency-dependent manner.

The results were presented today at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles, CA, U.S.1,2

Willie brings deep and relevant healthcare industry experience to Sunesis, most recently serving as CEO and Co-Founder of the private cancer immunotherapy company Bullet Biotechnology.

The company issues announcements regarding the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

Worldwide Clinical Trials has been recognized by Medidata, the leading global provider of cloud-based solutions and data analytics for clinical research, with the first annual Medidata Accelerator Award.

Zealand’s Annual General Meeting will be held on April 19, 2018.

The filing will become publicly available via the European Patent Register.

Fresenius Medical Care launched last week in Quanzhou its first independent dialysis center in China.

Medpace today announced the pricing of the previously announced secondary offering of 4,000,000 shares of its common stock by investment funds affiliated with Cinven Capital Management (V) General Partner Limited at a price to the public of $31.50 per share.